Table 1.
Clinical characteristics of the study population and comparison between subjects with and without PWS.
| Israeli cohort | Control | PWS | P value |
|---|---|---|---|
| N | 33 | 33 | – |
| Age (yr) | 28 ± 1.3 | 29 ± 1.4 | n.s. |
| DEL/UPD/IC | – | 19/13/1 | – |
| Sex (% male) | 50 | 50 | n.s. |
| Race (% Caucasian) | 100 | 100 | n.s. |
| BMI (kg/m2) | 28.9 ± 1.4 | 28.9 ± 1.4 | n.s. |
| BMI-Z | 1.2 ± 0.8 | 1.3 ± 0.8 | n.s. |
| AEA (pmol/mL) | 2.7 [2.1–3.3] | 3.0 [2.3–3.4] | n.s. |
| 2-AG (pmol/mL) | 10.6 [4.4–22.8] | 23.6 [13.0–38.2] | <0.001* |
| AA (nmol/mL) | 3.2 [2.2–4.1] | 7.5 [4.2–11.0] | <0.001* |
| N. American cohort | Control | PWS | P value |
|---|---|---|---|
| N | 23 | 23 | – |
| Age (yr) | 13.1 ± 6.3 | 11.4 ± 7.7 | n.s. |
| DEL/UPD/IC | – | 14/8/1 | – |
| Sex (% male) | 61 | 61 | n.s. |
| Race (% Caucasian) | 35 | 78 | 0.001* |
| BMI (kg/m2) | 24.8 ± 8.3 | 24.5 ± 10.0 | n.s. |
| BMI-Z | 1.2 ± 1.2 | 1.2 ± 1.2 | n.s. |
| AEA (pmol/mL) | 1.7 [1.2–1.9] | 1.5 [1.2–1.8] | n.s. |
| 2-AG (pmol/mL) | 16.2 [12.4–17.9] | 24.5 [16.6–42.0] | <0.001* |
| AA (nmol/mL) | 3.2 [2.5–3.9] | 4.1 [2.5–5.6] | n.s. |
Data are expressed as mean ± SD for normally distributed data or median [interquartile rage] for skewed data. * P < 0.001. Not significant (n.s.).